- HYTN Innovations Inc. (HYTN) has announced that it has successfully sold cannabis flower to serve the Australian medical cannabis market
- This was under the Promethean BioPharma brand.
- The sale was done in accordance with the company’s supply agreement with TCann Pty Ltd
- HYTN formulates, manufactures, markets, and sells cannabis goods
- HYTN Innovations Inc. (HYTN) opened trading today at $0.31 per share
HYTN Innovations (HYTN) has successfully sold cannabis flower to serve the Australian medical cannabis market under the Promethean BioPharma brand.
This was done in accordance with the company’s supply agreement with TCann Pty Ltd.
“HYTN has been sourcing superior dry flower cannabis inputs for its infused cannabis beverages and gummies for the last 12 months,” explained Jason Broome, Chief Operating Officer.
“We have now expanded our exports to TCann to provide high-quality cannabis flower that conforms to TGO100 (ICH regulations for inhalation of herbal products) alongside the four cannabis emulsions we were already selling in the Australian market,” he added.
“Our partnership with TCann demonstrates our commitment to growing revenues through an innovative approach to cannabis manufacturing,” noted Elliot McKerr, HYTN Chief Executive Officer.
Peter Comerford, CEO of Promethean and TCann commented on the news.
“This high-quality input material will be manufactured into finished goods and released for supply under our GMP License (TGA) and our Schedule 8 Manufacturing and Wholesale License (NSW) to Australian patients early this week.”
HYTN formulates, manufactures, markets, and sells cannabis goods.
HYTN Innovations Inc. (HYTN) opened trading today at $0.31 per share.
